Session 3A - Structural Biology & Lead Optimization - Harren Jhoti, Kendall Nettles
— Plenary - Fragment Based Discovery Using Rational Design - Harren Jhoti
— Structure-Based Drug Design for Nuclear Receptors - Kendal Nettles
— NMR Fragment Screening: Successful case study on protein-protein-interaction target - Venkat Thanabal
— 'Real-time' Crystallography: Developing a Synergy Between HTS & Structural Biology in Lead Discovery and Optimization - Thomas Stout

Session 3B - Target Biology & Screening - Therapeutic Specific Approaches - Gary Krishnan & Peter Lander
— Plenary - Development of Higher Quality Compound Screening Assays for Huntington's Disease Drug Discovery - Robert Pacifici
— Simplified High- Throughput Screening Assay for Differentiation of Antibacterial Lead Compounds - Bernard Weisblum
— Using Cytological Profiling as a Measure of Target Specificity for Identifying Novel Anti-mitotic Agents - Yama Abassi

Session 3D - ADME/Toxicology in Early Drug Discovery II - Kirk McMillan & Charles Crespi
— Plenary - The Application of P450 Inhibition Screens in Drug Discovery, an Update - Larry Wienkers
— Building a Second Generation Automated System for Complex Cell Culture & Assay - Janet Kolb
— Risk Assessment of in vivo Drug-interaction Potential & Cardiac Safety from HT P450 & hERG Inhibition Data - Gregor Zlokarnik

Session 4A - Knowledge Management: Extracting Value from Large Data Sets - Robert Brown & Phil McHale
— Plenary - Integrating, Inter-Linking and Mining Information to get New Insights - Trevor Heritage
— Systematic Processing and Cross-Assay Comparison of High-throughput Dose-response Screens - Joergen Nielsen
— Making a Difference with Screening Informatics - Magnus Kjellberg
— An Integrated Discovery Informatics Platform at Scripps Florida: Data Management, Analysis and Interpretation of Large Screening Data Sets for the Development of Novel Lead Series - Nicholas Tsinoremas

Session 4B - Defining Target & Compound Specificity - William Janzen & Doriano Fabbro
— Plenary - Drugging the Cancer Kinome: Meeting the Challenge of Combinatorial Therapeutic Strategies for Multigene Cancers - Paul Workman
— Developing High - Throughput Assays to Screen Protein Phosphatase Targets and Profiling the Inhibitor Specificity of the Chemical Probes Identified - Paul Johnston
— High-Throughput Approaches for the Identification of Novel Selective Small Molecule Modulators of Receptor Tyrosine Kinases - Kim Esposito
— Phosphorylation Profiling -High-Throughput Label-Free Detection of Protein-Protein Interactions With the Epic™ System - Meng Wu
— An Efficient, Rapid System for Profiling the Cellular Activities of Molecular Libraries - Jeremy Caldwell

Session 4C - Advanced Technology for Drug Discovery - Scott Diamond & David Weaver
— Plenary - Technologies for Improving Lead Optimization - John Houston
— Demonstration of the Physiological Relevance of Endogenous Cell-based Assays: Case Study Following GPCR Ligands from in-vitro Assays to an in-vivo Model - Siqi Lin
— Streamlining Early Drug Discovery by Parallel Integration of Postgenomic Technologies - Michael Blind
— See How They Run: Gait Dynamics in Blind Mice - Thomas Hampton
— GeXP: Highly Multiplexed Gene Expression Screening - Joseph Monforte

Session 4D - Imaging & High-Content Assays - Tina Garyantes & Renate Schnitzer
— Plenary - Automated Microscopy, Machine learning, systems biology, and drug delivery - Robert Murphy
— Impact of High-Content Screening on GPCR-target Drug Discovery - Ralf Heilker
— Rapid, High-Content Genome-Wide Assays Using Cell Microarrays - Anne Carpenter
— High-Content Analysis as a Tool for HTS Assay Development - Veronica Soloveva

Award Lecture Series - Awards Introduction and Presentation - Al Kolb & Ricardo Macarron